Mary M. Rozenman, See Remarks at Aimmune Therapeutics, Inc. (AIMT), sold 9,800 shares at $39.26 ($381K) on 2017-12-26, disclosed to the SEC on 2017-12-28.
Scheduled sale ($381k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.73 | 6,400 | $248K | 65.0% |
| 2 | $39.23 | 1,500 | $59K | 15.4% |
| 3 | $39.26 | 700 | $27K | 7.2% |
| 4 | $39.28 | 1,200 | $47K | 12.4% |
| Total | $38.91 avg | 9,800 | $381K | 100% |
| Filing → |
| AIMT | SELL | 2018-01-04 | $489K | — | Filing → |
| AIMT | SELL | 2017-09-11 | $675K | — | Filing → |
| AIMT | SELL | 2017-07-17 | $320K | — | Filing → |